文献速递基础与转化研究新药、器械与细胞基因治疗研发

嵌入三维层状人肝祖样细胞的体外生物人工肝缓解猪急性肝衰竭

An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigs.
PubMed 文献 · Sci Transl Med · 2020-01-01

研究开发了表达FOXA3的永生化人肝祖样细胞(HepLPCs),并在气液交互式生物人工肝(Ali-BAL)装置中形成三维高密度培养。在药物过量诱导的猪急性肝衰竭模型中,3小时体外Ali-BAL治疗使生存率从对照组17%和仅装置组0%提高至83%,并降低血氨、改善生化与凝血指标。

要点

  • Ali-BAL治疗3小时使猪急性肝衰竭生存率从17%提高至83%。
  • 治疗降低血氨、改善生化与凝血指标,减轻肝损伤和炎症。
  • 该装置有望成为急性肝衰竭的潜在治疗途径。

核心结论

  • 体外Ali-BAL治疗可预防肝性脑病并显著改善药物过量诱导的猪急性肝衰竭生存率。

研究设计与样本

  • 通过引入FOXA3构建永生化且功能增强的HepLPCs,在宏孔载体上于Ali-BAL装置中交替暴露于通气和营养形成三维培养。
  • 在药物过量诱导的猪急性肝衰竭模型中,比较Ali-BAL治疗、ALF对照和仅装置无细胞治疗,每组n=6。

主要发现

  • Ali-BAL治疗3小时使生存率为83%(n=6),显著高于ALF对照的17%(n=6,P=0.02)和仅装置组的0%(n=6,P=0.003)。
  • Ali-BAL治疗降低血氨浓度,并改善生化及凝血指标。
  • Ali-BAL治疗减轻肝损伤、改善炎症并增强肝再生。

关键数值与推荐

  • 生存率:Ali-BAL组83%(n=6)vs ALF对照组17%(n=6,P=0.02)vs 仅装置组0%(n=6,P=0.003)。
  • 治疗时长:体外Ali-BAL治疗3小时。

临床怎么用

  • Ali-BAL可作为急性肝衰竭的潜在体外治疗途径,需进一步临床验证。

局限性

  • 研究仅基于猪急性肝衰竭模型,样本量每组n=6,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical advancement of the bioartificial liver is hampered by the lack of expandable human hepatocytes and appropriate bioreactors and carriers to encourage hepatic cells to function during extracorporeal circulation. We have recently developed an efficient approach for derivation of expandable liver progenitor-like cells from human primary hepatocytes (HepLPCs). Here, we generated immortalized and functionally enhanced HepLPCs by introducing FOXA3, a hepatocyte nuclear factor that enables potentially complete hepatic function. When cultured on macroporous carriers in an air-liquid interactive bioartificial liver (Ali-BAL) support device, the integrated cells were alternately exposed to aeration and nutrition and grew to form high-density three-dimensional constructs. This led to highly efficient mass transfer and supported liver functions such as albumin biosynthesis and ammonia detoxification via ureagenesis. In a porcine model of drug overdose-induced acute liver failure (ALF), extracorporeal Ali-BAL treatment for 3 hours prevented hepatic encephalopathy and led to markedly improved survival (83%, n = 6) compared to ALF control (17%, n = 6, P = 0.02) and device-only (no-cell) therapy (0%, n = 6, P = 0.003). The blood ammonia concentrations, as well as the biochemical and coagulation indices, were reduced in Ali-BAL-treated pigs. Ali-BAL treatment attenuated liver damage, ameliorated inflammation, and enhanced liver regeneration in the ALF porcine model and could be considered as a potential therapeutic avenue for patients with ALF.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Li WJ, Zhu XJ, Yuan TJ, et al. An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigs. Sci Transl Med. 2020. PMID: 32641490. doi:10.1126/scitranslmed.aba5146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。